A critical evaluation of Optilume® BPH as a novel minimally invasive surgical treatment for the management of lower urinary tract symptoms in men

David C Chen; Alice Thomson; Siyu Huang; Declan G Murphy; Damien Bolton; Nathan Lawrentschuk; Marlon L Perera

doi:10.21037/tau-23-578

A critical evaluation of Optilume^® BPH as a novel minimally invasive surgical treatment for the management of lower urinary tract symptoms in men

Transl Androl Urol. 2024 Apr 30;13(4):653-656. doi: 10.21037/tau-23-578. Epub 2024 Apr 11.

Authors

David C Chen^{1

2

3

4}, Alice Thomson^{1

4}, Siyu Huang^{1

4}, Declan G Murphy^{1

4}, Damien Bolton^{2

4}, Nathan Lawrentschuk^{1

4

5}, Marlon L Perera^{1

2

4

5}

Affiliations

¹ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
² Department of Urology, Austin Health, Melbourne, Victoria, Australia.
³ Young Urological Researchers Organisation, Heidelberg, Victoria, Australia.
⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
⁵ Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

No abstract available

Keywords: Optilume® BPH; Prostate; benign prostate hyperplasia (BPH); minimally invasive surgical therapies (MIST).

Publication types

Editorial
Comment